SCHEMBL5385940

SCHEMBL5385940

CSc1ccnc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.61
CSNK1A1 P48729 2/20 0.44
CSNK1D P48730 2/20 0.44
CSNK1E P49674 1/20 0.44
SRC P12931 2/20 0.38
BRAF P15056 2/20 0.38
KDR P35968 2/20 0.38
GSK3B P49841 4/20 0.38
EGFR P00533 1/20 0.36
RAF1 P04049 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5385825 0.82 MAPK14 (0.60) MAPK14CSNK1A1CSNK1DCSNK1EGSK3B
SCHEMBL5383803 0.81 MAPK14 (0.58) MAPK14CSNK1A1CSNK1DCSNK1EGSK3B
SCHEMBL5391214 0.78 MAPK14 (0.76) MAPK14CSNK1A1CSNK1DCSNK1ESRC
Gw568326X SCHEMBL5391204 0.77 MAPK14 (0.64) MAPK14CSNK1A1CSNK1DCSNK1ESRC
SCHEMBL5379861 0.77 MAPK14 (0.55) MAPK14CSNK1A1CSNK1DCSNK1EGSK3B
SCHEMBL5388978 0.76 MAPK14 (1.00) MAPK14CSNK1A1CSNK1DCSNK1ESRC
SCHEMBL5382328 0.75 MAPK14 (0.58) MAPK14CSNK1A1CSNK1DCSNK1EGSK3B
SCHEMBL5388345 0.74 MAPK14 (0.57) MAPK14CSNK1A1CSNK1DCSNK1EGSK3B
SCHEMBL5389822 0.73 MAPK14 (0.65) MAPK14CSNK1A1CSNK1DCSNK1E
SCHEMBL5875487 0.73 MAPK14 (0.66) MAPK14CSNK1A1CSNK1DKDRGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166597-B2 Fused pyrazole derivatives being protein kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-01-23 US disclosed
EP-1311507-B1 FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS GLAXO GROUP LTD (GB) 2006-03-01 EP disclosed
US-20040053942-A1 Fused pyrazole derivatives bieng protein kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-03-18 US disclosed
EP-1311507-A1 FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-05-21 EP disclosed
WO-2002016359-A1 FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053942-A1 Fused pyrazole derivatives bieng protein kinase inhibitors RAF1, SBK3, MAP3K3 MAPK14 77/4885CSNK1A1 198/4885CSNK1D 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.